(Q38075152)

28 August 2017

1 reference

title

Kinase dysfunction and kinase inhibitors (English)

1 reference

28 August 2017

Cheryl A London

1 reference

28 August 2017

language of work or name

1 reference

1 February 2013

1 reference

28 August 2017

published in

Veterinary Dermatology

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

181-7.e39-40

1 reference

Cell signaling by receptor tyrosine kinases

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Receptor tyrosine kinases as targets for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Anaplastic lymphoma kinase in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Role of KIT and platelet-derived growth factor receptors as oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Epidermal growth factor receptor: a promising target in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

c-Met: structure, functions and potential for therapeutic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Vascular endothelial growth factor and other signaling pathways in developmental and pathologic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Promises and pitfalls of anti-angiogenic therapy in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

PI3K/Akt signalling pathway and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

PI3K/Akt and apoptosis: size matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

The Akt pathway: molecular targets for anti-cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Status of PI3K inhibition and biomarker development in cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

PTEN: life as a tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Cell-cycle targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

To cycle or not to cycle: a critical decision in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

RAS oncogenes: the first 30 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Oncogenic B-Raf mutations: crystal clear at last

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Genetic and epigenetic changes in lung carcinoma and their clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Monoclonal antibodies as therapeutic agents for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

First-line Herceptin monotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Treatment of HER2-positive breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Treatment strategy for HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Front-line management of diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

STI571: targeting BCR-ABL as therapy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Rational therapeutic intervention in cancer: kinases as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Resistance to imatinib (Glivec): update on clinical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Gastrointestinal stromal tumors: biology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Gastrointestinal stromal tumors: recent advances in understanding of their biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

The potential for crizotinib in non-small cell lung cancer: a perspective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Masitinib is safe and effective for the treatment of canine mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Acquired resistance to drugs targeting receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-3164.2012.01081.X

10.1111/J.1365-3164.2012.01081.X

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference